Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Poolbeg Pharma Plc has announced the appointment of Shore Capital Stockbrokers Limited as its new Joint Broker, complementing the existing financial advisory team that includes Cavendish Capital Markets Ltd and J&E Davy. The company, which focuses on developing innovative medicines for diseases with a high unmet medical need, aims to replicate the success of Amryt Pharma by generating near-term revenues and creating shareholder value. Poolbeg Pharma is advancing its clinical programs in areas such as cancer, infectious disease, and metabolic conditions using a cost-effective development strategy and AI-led research.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.
